Key takeaways:
- Elinzanetant's (Lynkuet) NK1 and NK3 dual receptor antagonism makes it a logical choice for women with both VMS and significant sleep disruption who are not candidates for or prefer to avoid hormone therapy, though it remains one of several available options rather than a default.
- Liver function monitoring requirements differ between agents: Fezolinetant (Veozah) requires testing at baseline and months 1 through 9, whereas elinzanetant requires only baseline and 3-month monitoring—a practical distinction that may influence patient preference.
- Effective sleep counseling in midlife women requires accounting for non-VMS contributors—caregiving demands, anxiety, nocturia, and pets — that VMS treatment alone will not resolve, and follow-up at 2 to 3 months is essential to assess whether treatment is working.
Selecting among the growing menu of non-hormonal options for vasomotor symptoms and sleep disruption in menopausal women ultimately comes down to patient preference, contraindications, and willingness to engage with monitoring requirements—with shared decision-making and timely follow-up as the practical pillars of effective management, according to Stephanie S. Faubion, MD, MBA, FACP, MSCP, IF, director of the Mayo Clinic Center for Women's Health and medical director of The Menopause Society.
For women who are not candidates for or who prefer to avoid hormone therapy and who present with both vasomotor symptoms and sleep disruption, elinzanetant's (Lynkuet) dual NK1 and NK3 receptor antagonism offers a meaningful advantage over fezolinetant's (Veozah) NK3-selective profile.
"If a woman comes in with a lot of vasomotor symptoms and a sleep disturbance and she's not a candidate for hormone therapy or chooses not to use it, then elinzanetant would certainly be a great option," Faubion said. She was careful, however, to frame this as one option among several rather than a default.
"I don't want women to think that's the only option they have."
On the question of tracking sleep outcomes in clinical practice, Faubion was deliberately practical. Validated instruments such as the Epworth Sleepiness Scale, the Pittsburgh Sleep Quality Index, and the STOP-BANG questionnaire for sleep apnea screening exist and can provide more objective data—but she stopped short of recommending routine questionnaire administration.
"I think most women are going to be able to tell you if they're sleeping well or not sleeping well," she said.
What the clinical conversation does need to capture, she emphasized, is the full range of factors keeping midlife women awake. These extend well beyond VMS and primary insomnia: caregiving responsibilities for aging parents or children, anxiety about teenagers or adult children still at home, a stressful job, nocturnal rumination, aging pets requiring nighttime trips outside, and nocturia can all fragment sleep in ways that no VMS treatment will address.
"We need to be thinking about all of those things," Faubion said.
In shared decision-making conversations, Faubion described a process that moves through contraindications, patient preferences, and monitoring tolerability in parallel. Some patients arrive having already ruled out hormone therapy or antidepressants; others prioritize simplicity, preferring a once-daily oral medication. Some prefer to avoid medication entirely—and cognitive behavioral therapy, she noted, has evidence supporting its use for both vasomotor symptoms and insomnia. For patients considering fezolinetant or elinzanetant, the liver function monitoring requirements differ: Fezolinetant requires testing at baseline and at months 1, 2, 3, 6, and 9, whereas elinzanetant requires baseline and 3-month testing only—a distinction that may matter to some patients.
"Patients will only take what they feel comfortable taking and what will actually work," Faubion said. Follow-up at 2 to 3 months is essential to assess response, address tolerability, and adjust treatment as needed.
